FDA Finds MOLD at Drug Suppliers! What GLP-1 Patients Need to Know
The Downsized — FDA Finds MOLD at Drug Suppliers! What GLP-1 Patients Need to Know
Channel: DOWNSIZED · Our label: Patient-experience channel — GLP-1 journey, daily · Source: youtube.com/watch?v=vWugS5h3cf4
What this video covers
This week, FDA inspectors uncover serious problems at overseas drug ingredient suppliers, and we look at what the findings do and don’t tell us about the safety of compounded weight loss medications. We also have a CBS investigation into products sold as redatride. New GLP-1 research from Lily and Novo and a promising weight loss pill moving into phase three trials. Welcome back to the downsized, or in fact, the downsized news.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- This week, FDA inspectors uncover serious problems at overseas drug ingredient suppliers, and we look at what the findings do and don’t tell us about the safety of compounded weight loss medications.
- Kevin Duffen Lily’s vice president of aging research presented findings from a sub study of Surmount 5, the clinical trial comparing traceide with simaglutide.
- Although animal findings cannot establish that a medication will extend human life, the clinical evidence already establishes important benefits of GLP-1 medications for several serious health conditions.
- Red True Tide may eventually become an important approved treatment for obesity, but the clinical results don’t establish the safety or identity of products being sold under its name today.
- Those results came from a relatively short study and the longer phase three trials will provide more information about sustained weight loss, gastrointestinal side effects, and treatment discontinuation.
- Novanorisk received an FDA warning letter in March over serious deficiencies in how it collected, evaluated, and reported adverse drug events.
Read next
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.